{"id":745045,"date":"2014-01-13T08:30:00","date_gmt":"2014-01-13T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/"},"modified":"2023-03-22T00:05:00","modified_gmt":"2023-03-22T04:05:00","slug":"merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/","title":{"rendered":"Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma"},"content":{"rendered":"<p class=\"bwalignc\">       Expects to Complete Application in First Half of 2014     <\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      said today it has started a rolling submission to the U.S. Food and Drug<br \/>\n      Administration (FDA) of a Biologics License Application for MK-3475, the<br \/>\n      company\u2019s investigational anti-PD-1 immunotherapy, for patients with<br \/>\n      advanced melanoma who have been previously treated with ipilimumab. A<br \/>\n      rolling submission allows completed portions of the application to be<br \/>\n      submitted and reviewed by the FDA on an ongoing basis. The company<br \/>\n      expects to complete the application in the first half of 2014.\n    <\/p>\n<p>\n      \u201cOur MK-3475 is a novel immunomodulatory molecule that holds promise for<br \/>\n      patients with advanced malignancy who now have limited treatment<br \/>\n      options,\u201d said Roger M. Perlmutter, M.D., Ph.D., president, Merck<br \/>\n      Research Laboratories. \u201cInitiation of this rolling submission represents<br \/>\n      an important milestone in the MK-3475 clinical development program for<br \/>\n      patients suffering from malignant melanoma.\u201d\n    <\/p>\n<p>\n      <b>Clinical Development of MK-3475 in Advanced Melanoma<\/b>\n    <\/p>\n<p>\n      MK-3475 is currently being studied in three clinical trials for advanced<br \/>\n      melanoma including a Phase III trial of MK-3475 versus ipilimumab in<br \/>\n      ipilimumab-na\u00efve advanced melanoma patients (PN 006). Enrollment is<br \/>\n      complete in the advanced melanoma cohorts in the company\u2019s Phase IB<br \/>\n      trial (PN 001) and the Phase II trial (PN 002) comparing two doses of<br \/>\n      MK-3475 versus chemotherapy in patients with advanced melanoma who have<br \/>\n      progressed after prior therapy. In April 2013, Merck announced that<br \/>\n      MK-3475 received a Breakthrough Therapy designation for advanced<br \/>\n      melanoma from the FDA.\n    <\/p>\n<p>\n      <b>About MK-3475<\/b>\n    <\/p>\n<p>\n      Many tumors are able to evade the immune system through a mechanism that<br \/>\n      exploits the PD-1 inhibitory checkpoint protein. MK-3475 is an<br \/>\n      investigational, highly selective anti-PD-1 immunotherapy designed to<br \/>\n      restore the natural ability of the immune system to recognize and target<br \/>\n      cancer cells by selectively achieving dual ligand blockade (PD-L1 and<br \/>\n      PD-L2) of the PD-1 protein. By blocking PD-1, MK-3475 enables activation<br \/>\n      of the immune system\u2019s T-cells that target cancer by essentially<br \/>\n      releasing a brake on the immune system.\n    <\/p>\n<p>\n      MK-3475 is currently being studied in 10 clinical trials estimated to<br \/>\n      enroll more than 4,000 patients across a broad range of cancer types<br \/>\n      including: bladder, colorectal, gastric, head and neck, melanoma,<br \/>\n      non-small cell lung, renal, triple negative breast and hematological<br \/>\n      malignancies. Additional trials, both as monotherapy and in combination<br \/>\n      with other cancer therapies, are planned. For information on Merck\u2019s<br \/>\n      clinical trials please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2F&amp;esheet=50781806&amp;newsitemid=20140113005937&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2F&amp;index=1&amp;md5=3fd7f7391c7a730c013dcd928feb06a3\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/clinical-trials\/<\/a>.\n    <\/p>\n<p>\n      <b>About Advanced Melanoma<\/b>\n    <\/p>\n<p>\n      Melanoma is the most dangerous type of skin cancer. While it accounts<br \/>\n      for only 5 percent of all cases, melanoma is the cause of 75 percent of<br \/>\n      skin cancer deaths. According to the American Cancer Society, an<br \/>\n      estimated 9,180 people in the U.S. died from advanced melanoma in 2012.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=50781806&amp;newsitemid=20140113005937&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=e40e5bfa788d6941cfd2d5bfb19428b6\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=50781806&amp;newsitemid=20140113005937&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=2c47e54d7fd4a1fc0ac6d3fede091d95\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=50781806&amp;newsitemid=20140113005937&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=cd5137b306996d8c14a44c2324d99967\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=50781806&amp;newsitemid=20140113005937&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=93ee5994d5942dff6a439bcc21e23ddd\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=50781806&amp;newsitemid=20140113005937&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=cfa360a632255d0753cd0a2a03deba6d\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140113005937r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, 908-423-3046<br \/>Claire        Mulhearn, 908-423-7425<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-500-1101<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has started a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application for MK-3475, the company\u2019s investigational anti-PD-1 immunotherapy, for patients with advanced melanoma who have been previously treated with ipilimumab. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The company expects to complete the application in the first half of 2014. \u201cOur MK-3475 is a novel immunomodulatory molecule that holds promise for patients with advanced malignancy who now have limited treatment options,\u201d said Roger M. Perlmutter, M.D., Ph.D., president, Merck Research Laboratories. \u201cInitiation of this rolling submission represents an important milestone in the MK-3475 clinical development program for patients suffering from malignant melanoma.\u201d Clinical Development of MK-3475 in Advanced Melanoma<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289,56],"class_list":["post-745045","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has started a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application for MK-3475, the company\u2019s investigational anti-PD-1 immunotherapy, for patients with advanced melanoma who have been previously treated with ipilimumab. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The company expects to complete the application in the first half of 2014. \u201cOur MK-3475 is a novel immunomodulatory molecule that holds promise for patients with advanced malignancy who now have limited treatment options,\u201d said Roger M. Perlmutter, M.D., Ph.D., president, Merck Research Laboratories. \u201cInitiation of this rolling submission represents an important milestone in the MK-3475 clinical development program for patients suffering from malignant melanoma.\u201d Clinical Development of MK-3475 in Advanced Melanoma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:05:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/\",\"name\":\"Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-01-13T08:30:00+00:00\",\"dateModified\":\"2023-03-22T04:05:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has started a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application for MK-3475, the company\u2019s investigational anti-PD-1 immunotherapy, for patients with advanced melanoma who have been previously treated with ipilimumab. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The company expects to complete the application in the first half of 2014. \u201cOur MK-3475 is a novel immunomodulatory molecule that holds promise for patients with advanced malignancy who now have limited treatment options,\u201d said Roger M. Perlmutter, M.D., Ph.D., president, Merck Research Laboratories. \u201cInitiation of this rolling submission represents an important milestone in the MK-3475 clinical development program for patients suffering from malignant melanoma.\u201d Clinical Development of MK-3475 in Advanced Melanoma","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:05:00+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/","name":"Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-01-13T08:30:00+00:00","dateModified":"2023-03-22T04:05:00+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-rolling-submission-of-u-s-biologics-license-application-for-mk-3475-an-investigational-anti-pd-1-immunotherapy-in-patients-with-advanced-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9bfd4f06-c891-4d6b-b33e-935e70c4b067","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Initiates-Rolling-Submission-of-US-Biologics-License-Application-for-MK-3475-an-Investigational-Anti-PD-1-Immunotherapy-in-Pati-AGXUY.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745045\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745045"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}